GANX (Gain Therapeutics) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GANX Gain Therapeutics Inc GANX
23 GF Score
Price $1.69
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

GANX vs PYPD, MAIA, ACET: Short Percentage of Float Comparison

For the Biotechnology subindustry, Gain Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gain Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gain Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Gain Therapeutics's Short Percentage of Float falls into.


GANX
23GF Score
Gain Therapeutics Inc GANX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
23GF Score

Get the complete analysis for GANX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.69
Price